Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The companys lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The companys product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
November 14, 2022
RegMed Investors’ (RMi) pre-open: after an upside ending week
November 11, 2022
RegMed Investors’ (RMi) closing bell: closing out the week booking gains
November 11, 2022
RegMed Investors’ (RMi) pre-open: post massive gains, what usually follows is pain
November 10, 2022
RegMed Investors’ (RMi) closing bell: the risk-on fervor sent markets skyward and sector upward
November 10, 2022
RegMed Investors’ (RMi) pre-open: CPI, up +0.4% versus +0.6% estimate
November 9, 2022
RegMed Investors’ (RMi) closing bell: down sliding markets and sector responds to incomplete election results
November 9, 2022
RegMed Investors’ (RMi) pre-open: stock futures trade lower as election results are tallied
November 8, 2022
RegMed Investors’ (RMi) closing bell: after five (5) down sessions, it was inevitable that the algorithms would “rule”
November 8, 2022
RegMed Investors’ (RMi) pre-open: vote your conscious and your portfolio
November 7, 2022
RegMed Investors’ (RMi) closing bell: election and economics will determine the week as negative momentum moves the sector today
35 companies, 1 interpreter!
Insight, foresight and recommendation
Verastem (VSTM) -- Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.